GenSight Biologics SA(DE:G49N)
€0.07+0.00 (+1.47%)
DE:G49N
GenSight Biologics SA stock drug pipeline
€0.07
At close:+0.00 (+1.47%)
GenSight Biologics SA (G49N) Drug Pipeline
1 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Gs010, Gs010 High Dose, Gs010 Low Dose | Leber Hereditary Optic Disease | Phase II | Recruiting | Efficacy and Safety Study of Bilateral IVT Injection of GS010 at Two Dose Levels in LHON Patients | Dec 11, 2025 | ― |
| Gs010, Sham Intravitreal Injection | Leber Hereditary Optic Neuropathy | Phase III | Completed | RESCUE and REVERSE Long-term Follow-up | Jan 15, 2018 | ― |
| Gene Therapy: Gs030-Dp And Medical Device: Gs030-Md | Non-Syndromic Retinitis Pigmentosa | phase1AndPhase2 | Active Not Recruiting | Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa | Oct 11, 2017 | ― |
| Gs010 | Leber Hereditary Optic Neuropathy | Phase III | Completed | Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year | Sep 19, 2017 | ― |
| Gs010, Sham Intravitreal Injection | Optic, Atrophy, Hereditary, Leber | Phase III | Completed | Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE) | Jan 07, 2016 | ― |
| Gs010, Sham Intravitreal Injection | Optic, Atrophy, Hereditary, Leber | Phase III | Completed | Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation | Jan 07, 2016 | ― |
| Gs010 | Leber Hereditary Optic Neuropathy | phase1AndPhase2 | Completed | Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients | Feb 13, 2014 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Gs010, Gs010 High Dose, Gs010 Low Dose | Phase II | Leber Hereditary Optic Disease | Recruiting | Efficacy and Safety Study of Bilateral IVT Injection of GS010 at Two Dose Levels in LHON Patients | Dec 11, 2025 | ― |
| Gs010, Sham Intravitreal Injection | Phase III | Leber Hereditary Optic Neuropathy | Completed | RESCUE and REVERSE Long-term Follow-up | Jan 15, 2018 | ― |
| Gene Therapy: Gs030-Dp And Medical Device: Gs030-Md | phase1AndPhase2 | Non-Syndromic Retinitis Pigmentosa | Active Not Recruiting | Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa | Oct 11, 2017 | ― |
| Gs010 | Phase III | Leber Hereditary Optic Neuropathy | Completed | Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year | Sep 19, 2017 | ― |
| Gs010, Sham Intravitreal Injection | Phase III | Optic, Atrophy, Hereditary, Leber | Completed | Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE) | Jan 07, 2016 | ― |
| Gs010, Sham Intravitreal Injection | Phase III | Optic, Atrophy, Hereditary, Leber | Completed | Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation | Jan 07, 2016 | ― |
| Gs010 | phase1AndPhase2 | Leber Hereditary Optic Neuropathy | Completed | Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients | Feb 13, 2014 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does GenSight Biologics (DE:G49N) have in its pipeline
GenSight Biologics SA DE:G49N is currently developing the following drugs: Gs010, Gs010 High Dose, Gs010 Low Dose, Gs010, Sham Intravitreal Injection, Gene Therapy: Gs030-Dp And Medical Device: Gs030-Md, Gs010. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

